Breaking Down SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Novavax, Inc.

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Over the past decade, Catalyst Pharmaceuticals, Inc. and Novavax, Inc. have demonstrated contrasting trajectories in their SG&A expenditures. From 2014 to 2023, Catalyst Pharmaceuticals saw a staggering increase of nearly 2,900% in their SG&A expenses, reflecting their aggressive expansion and strategic investments. In contrast, Novavax, Inc. experienced a more moderate rise of approximately 2,300%, peaking in 2022. This divergence highlights the different strategic approaches these companies have taken in navigating the biotech landscape. As of 2023, Novavax's SG&A expenses are about 3.5 times higher than those of Catalyst, underscoring their larger operational scale. These insights provide a window into how each company allocates resources to drive their respective missions forward.